Convert VitaFOXO VITAFOXO to Checkmate CHECK

This project will design a new RNA therapeutic that nudges the longevity-linked FOXO3 gene into its health-promoting form to halt the tissue breakdown behind degenerative disc disease—opening a precise, scalable route to drugs that extend healthspan. Dr. Lorna Harries’ lab has identified an innovative way to modulate FOXO3, a well known and yet undrugged longevity target, and propose leveraging it to address chronic lower back pain stemming from degenerative disc disease. They plan to make short, lab-made modified RNA molecules (antisense oligonucleotides) that selectively switch FOXO3’s “good” message on, first in human cells and mini-disc models. Success would yield 1) a lead drug candidate, 2) proof it can restore disc health, and 3) the data needed for patenting and further development. The same molecules could later be adapted to treat many other age-related conditions, helping people stay healthy for longer.

Chess remains one of the most widely played and culturally significant games in history. With over 605.0 million players globally and over $2.5 billion in market value, its recent resurgence, driven by digital platforms, live streaming, and global accessibility, has brought the game to new audiences. Yet despite this momentum, the digital chess experience has remained largely unchanged. It continues to be the same game, with the same rules and mechanics. Anichess looks to modernize chess and reimagine the timeless game. By integrating spell-based mechanics, digital ownership, and player-driven governance, it reimagines chess as an interactive, evolving ecosystem. Anichess transforms the game as a new title that looks to advance chess adoption, giving seasoned players a twist to the game they love and empowering newer players by giving them an even playing field to enter the game and test their skills.